1372149-51-3

Upstream product

• 1262116-36-8 (S)-(S)-3-oxiranylpyrrolidine-1-carboxylic acid t-butyl ester 
• 1262116-18-6 (S)-(S)-3-oxiranylpyrrolidine-1-carboxylic acid t-butyl ester 
• 1262116-19-7 (S)-3-((S)-1,2-dihydroxyethyl)pyrrolidine-1-carboxylic acid t-butyl ester 
• 1228312-14-8 (R)-3-vinylpyrrolidine-1-carboxylic acid t-butyl ester 
• 402-44-8 4-Fluorobenzotrifluoride 
• 1372149-49-9 C₁₂H₂₃NO₃S 

Downstream Products

• 1372256-49-9 (S)-3-[(S)-2-Methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine 
• 1372149-58-0 C₁₉H₂₆F₃NO₅S 
• 1372149-59-1 (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine hydrochloride salt 

Relevant academic research and scientific papers

CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND

The invention provides crystalline hydrochloride salts of (S)-3-[(S)-2-methanesulfonyl-1-(4-trifluoromethylphenoxy)ethyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salts, processes and intermediates for preparing the crystalline salts, and methods of using the crystalline salts to treat diseases.

SEROTONIN REUPTAKE INHIBITORS

In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.